THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Tech firms wary on biodefense

Say latest US plan sidesteps concerns on liability, funding

By Ross Kerber
Globe Staff / June 18, 2004

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

  • E-mail|
  • Print|
  • Reprints|
  • |
Text size +

Even as Congress finalizes a bill to fund vaccines and other countermeasures against bioterror attacks, many executives say the much-ballyhooed measures from Washington have sidestepped the toughest issues facing the drug industry. (Full Article: 931 Words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 Article
  • $9.95 4 Articles
  • $99.95 Unlimited